Hafiz Abdul-Aziz

Dr. Mohd Hafiz Abdul-Aziz is an incoming National Health and Medical Research Council (NHMRC) Emerging Leadership Fellow EL2 (2026) and Clinical Research Pharmacist at the University of Queensland Centre for Clinical Research (UQCCR), Australia. He currently leads the Clinical Dosing Studies and Knowledge Translation Workstream within the Antimicrobial Optimisation Group and the Centre for Research Excellence for Personalising Antimicrobial Dosing to Reduce Resistance (CRE RESPOND) at UQCCR. Dr. Abdul-Aziz holds a Bachelor of Pharmacy (IIUM) and a Master of Clinical Pharmacy (UKM) from Malaysia and completed his PhD at the University of Queensland in 2016. His doctoral thesis focused on pharmacokinetic/pharmacodynamic (PK/PD)-optimised beta-lactam dosing in critically ill patients.

As a clinical pharmacist with a strong interest in clinical research, Dr. Abdul-Aziz is particularly focused on multi-centre and multi-national collaborations. His current research program aims to develop innovative methods for optimising antimicrobial dosing and delivery to improve patient outcomes in the ICU. His current areas of interest include: (1) antimicrobial pharmacokinetics/pharmacodynamics (PK/PD); (2) antimicrobial dosing in special patient population groups (e.g. critically ill, pneumonia, extracorporeal membrane oxygenation (ECMO), renal replacement therapy (RRT) patients; (3) prolonged infusions of beta-lactam antibiotics; (4) antimicrobial therapeutic drug monitoring (TDM); (5) ex-vivo pharmacokinetic ECMO and RRT model experiments; (6) model-informed precision antimicrobial dosing; and (7) multi-centre population pharmacokinetic studies. He has authored over 80 peer-reviewed papers and book chapters in this research area. His publications have been cited more than 4800 times. He has extensive experience in designing and conducting multi-national clinical pharmacokinetic studies in the ICU. Over the past five years, he has led or coordinated eight multi-national antimicrobial pharmacokinetic studies, including the ASAP ECMO, BLING 3, BLING 3 PK/PD, and PNEUDOS studies.

Dr. Abdul-Aziz is a Fellow of the International Society of Antimicrobial Chemotherapy (ISAC) and currently serves as the Chair of the Infections in the ICU and Sepsis Working Group of ISAC. He maintains active collaborations with more than 100 researchers across 36 countries.

Information for Potential Students

Dr. Abdul-Aziz welcomes expressions of interest from prospective postgraduate students. Interested applicants are encouraged to contact him via email to discuss potential research opportunities. Please include an up-to-date CV and a brief research proposal outlining the project you wish to undertake. Dr. Abdul-Aziz is also open to developing projects that address research questions specific to your clinical practice, particularly those related to optimising antimicrobial dosing and delivery.